{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027168","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.242174+00:00","generated_at":"2026-06-21T19:14:54.557473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M","bullets":["Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.","Operating income fell to $30K from $585K in the year-ago quarter.","Net loss of $35K ($0.00 EPS) vs net income of $516K ($0.02) in Q1 FY2022.","Two largest Contract Manufacturing customers were 85% of revenue (down from 91%).","Co-CEOs cite pandemic overstocking by customers as key headwind."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027168","json":"https://secwatch.observer/filing/0001437749-22-027168.json","markdown":"https://secwatch.observer/filing/0001437749-22-027168.md","text":"https://secwatch.observer/filing/0001437749-22-027168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/0001437749-22-027168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/inbp20221110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:14:54.557473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69b8122b0cb5d4a455803f341d5811853c020c31","claim":"INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.","evidence_excerpt":"Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 HILLSIDE, NEW JERSEY (November 10, 2022) - Integrated BioPharma, Inc. (OTCQX: INBP) (the \"Company\" or \"INBP\") reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/0001437749-22-027168-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$12.3 million"},{"label":"Net income","value":"net loss of approximately $35,000 or $0.00 per share of common stock"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}